Perrigo Completes €305.6M Sale of Dermacosmetics Business, Bolstering Balance Sheet

summarizeSummary

Perrigo completed the sale of its Dermacosmetics business for €305.6 million upfront, a move expected to reduce debt and streamline its portfolio.

check_boxKey Events

• Divestiture Completed

  Perrigo completed the sale of its Dermacosmetics branded business to Karo Healthcare, as previously agreed on July 13, 2025.

• Significant Cash Proceeds

  The company received €305.6 million in upfront cash, including net working capital adjustments, with potential for an additional €27.0 million in contingent consideration over three years.

• Strategic Debt Reduction

  Proceeds from the sale will primarily be used to reduce debt, enhancing financial flexibility and strengthening the balance sheet, a critical step following a $1.43 billion net loss in 2025.

• Portfolio Streamlining

  The divestiture of the Dermacosmetics business, which generated approximately €120 million in net sales in 2025, aligns with Perrigo's 'Three-S plan' to stabilize, streamline, and strengthen the company.

auto_awesomeAnalysis

Perrigo has finalized the divestiture of its Dermacosmetics branded business, receiving €305.6 million in upfront cash. This strategic move, which follows the company's recent significant net loss and goodwill impairment disclosed in its 10-K, is aimed at streamlining its portfolio, focusing on core categories, and primarily reducing debt. The transaction enhances financial flexibility and strengthens the balance sheet, addressing a critical need highlighted by the company's financial baseline.